Aerie Pharmaceuticals Inc. (AERI)

18.40
0.55 3.08
NASDAQ : Health Technology
Prev Close 17.85
Open 18.00
Day Low/High 17.15 / 18.56
52 Wk Low/High 17.51 / 50.10
Volume 1.13M
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 46.32M
Market Cap 874.08M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Noteworthy Tuesday Option Activity: AERI, OA, CVNA

Noteworthy Tuesday Option Activity: AERI, OA, CVNA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aerie Pharmaceuticals Inc , where a total volume of 11,652 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 264.7% of AERI's average daily trading volume over the past month, of 440,260 shares.

Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals To Present At The Stifel 2017 Healthcare Conference

Aerie Pharmaceuticals To Present At The Stifel 2017 Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals To Announce Third Quarter 2017 Financial Results And Host Conference Call On Wednesday, November 8, 2017

Aerie Pharmaceuticals To Announce Third Quarter 2017 Financial Results And Host Conference Call On Wednesday, November 8, 2017

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2017 financial results will be released after the market closes on Wednesday, November 8, 2017.

Aerie Pharmaceuticals Announces Appointment Of John Maltman, Ph.D., As Vice President Of Medical Affairs

Aerie Pharmaceuticals Announces Appointment Of John Maltman, Ph.D., As Vice President Of Medical Affairs

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces FDA Advisory Committee Vote In Favor Of Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals Announces FDA Advisory Committee Vote In Favor Of Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals Stock Trading Halted Today

Aerie Pharmaceuticals Stock Trading Halted Today

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers

Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers

The Burlington, Mass.-based firm announced a proposed public offering of 4 million shares. It plans to use part of the net proceeds to fund manufacturing and commercialization of osteoarthritis knee pain treatment Zilretta.

Aerie Pharmaceuticals Announces Appointment Of New Members Of Its Research And Development Team

Aerie Pharmaceuticals Announces Appointment Of New Members Of Its Research And Development Team

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition To Further Advance Its Retinal Disease Program

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition To Further Advance Its Retinal Disease Program

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals Announces Appointment Of Ann Keevans As Director Of Human Resources - Europe

Aerie Pharmaceuticals Announces Appointment Of Ann Keevans As Director Of Human Resources - Europe

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of New Members Of Its Commercialization Team

Aerie Pharmaceuticals Announces Appointment Of New Members Of Its Commercialization Team

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of Sheila Elliott, PharmD, As Western Regional Director Of Medical Science Liaisons

Aerie Pharmaceuticals Announces Appointment Of Sheila Elliott, PharmD, As Western Regional Director Of Medical Science Liaisons

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals Announces Appointment Of Tori Arens As Vice President Of Drug Product Manufacturing And Eric Carlson, Ph.D. As Vice President Of Research And Development

Aerie Pharmaceuticals Announces Appointment Of Tori Arens As Vice President Of Drug Product Manufacturing And Eric Carlson, Ph.D. As Vice President Of Research And Development

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other...

Short Interest Increases 18.3% For AERI

Short Interest Increases 18.3% For AERI

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 809,364 share increase in total short interest for Aerie Pharmaceuticals Inc , to 5,230,594, an increase of 18.31% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Aerie Pharmaceuticals To Present At Two Investor Conferences In September

Aerie Pharmaceuticals To Present At Two Investor Conferences In September

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%

Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals Announces Appointment Of Deanne Melloy As Vice President Of Marketing And Norbert Lowe As Regional Sales Director

Aerie Pharmaceuticals Announces Appointment Of Deanne Melloy As Vice President Of Marketing And Norbert Lowe As Regional Sales Director

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of Isabel Moredo, PharmD, As Eastern Regional Director Of Medical Science Liaisons

Aerie Pharmaceuticals Announces Appointment Of Isabel Moredo, PharmD, As Eastern Regional Director Of Medical Science Liaisons

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Comments On Notification From Contract Manufacturer

Aerie Pharmaceuticals Comments On Notification From Contract Manufacturer

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference

Aerie Pharmaceuticals To Present At The Canaccord Genuity Growth Conference

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals Enters Into Collaboration Agreement With DSM Focused On Technology To Potentially Deliver Aerie Compounds To Treat Retinal Diseases Such As Wet AMD

Aerie Pharmaceuticals Enters Into Collaboration Agreement With DSM Focused On Technology To Potentially Deliver Aerie Compounds To Treat Retinal Diseases Such As Wet AMD

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals To Announce Second Quarter 2017 Financial Results And Host Conference Call On Tuesday, August 1, 2017

Aerie Pharmaceuticals To Announce Second Quarter 2017 Financial Results And Host Conference Call On Tuesday, August 1, 2017

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced today that its second quarter 2017 financial results will be released after the market closes on Tuesday, August 1, 2017.

Aerie Pharmaceuticals Announces Appointment Of Richard A. Halprin As Director Of Professional Affairs

Aerie Pharmaceuticals Announces Appointment Of Richard A. Halprin As Director Of Professional Affairs

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals To Present At Two Investor Conferences In June

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.

Aerie Pharmaceuticals Raises $125 Million In ATM Sales And Upsized Follow-On Offering

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

TheStreet Quant Rating: D- (Sell)